Basic information about sacituzumab govitecan
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer | Future Oncology
Form 8-K IMMUNOMEDICS INC For: Jun 01
FDA Grants Antibody-Drug Conjugate Breakthrough Designation in Triple Negative Breast Cancer – Amani Khawatmi, Contributor | Cancer Biology
ESMO 2020: Sacituzumab Govitecan Significantly Extends Overall Survival in Patients with mTNBC - Onco'Zine
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer - National Cancer Institute
Pharmaceuticals | Free Full-Text | Antibody–Drug Conjugates: The Last Decade | HTML
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). - Abstract - Europe PMC
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies - ScienceDirect
Trodelvy for the Treatment of Advanced Triple-Negative Breast Cancer
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial - Annals of Oncology
Depiction of inotuzumab ozogamicin's mechanism of action in tumor... | Download Scientific Diagram
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond | SpringerLink
Immunomedics triple negative breast cancer ADC drug rejected by FDA in the United States – Creative Biolabs ADC Blog
Emerging Novel Therapeutics in Triple-Negative Breast Cancer | SpringerLink
Sacituzumab govitecan-hziy – Drug Approvals International
Mechanism of action of ADCs | Download Scientific Diagram
Antibody–Drug Conjugates | Encyclopedia
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan,European Journal of Medicinal Chemistry - X-MOL
Immunomedics Competitor Threatens To Leapfrog Approval With Breakthrough Therapy Designation (OTCMKTS:CYDY) | Seeking Alpha
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments | SpringerLink
Antibody–Drug Conjugates | Encyclopedia
Sacituzumab Govitecan: First Approval | SpringerLink
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer | Biochempeg
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index | Clinical Cancer Research
